Trials / Unknown
UnknownNCT04811443
DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empegfilgrastim | Extimia® |
Timeline
- Start date
- 2021-01-12
- Primary completion
- 2022-06-12
- Completion
- 2022-06-12
- First posted
- 2021-03-23
- Last updated
- 2021-03-23
Locations
3 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT04811443. Inclusion in this directory is not an endorsement.